Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin - Wikidata - awgldk - TriplyDB

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

http://www.wikidata.org/entity/Q28200198

about

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.Anticoagulation by factor Xa inhibitors.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.Pharmacodynamic and pharmacokinetic basics of rivaroxaban.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.Stroke Prevention in Atrial Fibrillation: Where are We Now?Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin.Rivaroxaban delivery and reversal at a venous flow rate New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis Practical management of new oral anticoagulants after total hip or total knee arthroplasty.Rivaroxaban: a novel, oral, direct factor Xa inhibitor.Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.Will warfarin ever be replaced?The quest for new anticoagulants: from clinical development to clinical practice.Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors).Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.The discovery and development of rivaroxaban.Inhibitors of propagation of coagulation: factors V and X.Rivaroxaban in the contemporary treatment of acute coronary syndromes.Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.New anticoagulants for the prevention of stroke in atrial fibrillation.Oral factor Xa and direct thrombin inhibitors: a clinical perspective.Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.Drug interactions with rivaroxaban following total joint replacement surgery.New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.The discovery of rivaroxaban: translating preclinical assessments into clinical practice.

P2860

Q26781181-526A6B5D-8DE9-46D7-84EF-F947FB60411E Q26828817-75861615-0E4B-4DE6-B49F-22992AA6ED70 Q26864411-A05A743B-9A5B-4BD8-A830-BE4854D8DDFB Q28087447-FA4B70CA-17CE-464D-A06F-52680DF12D29 Q28250157-7147F95D-3568-4305-853F-1BA5744468FA Q30429127-D25BAC2D-FAC3-4150-8C29-A4D9071B664F Q33997674-D34F7DA8-8B1B-454E-ADE5-0C4FDFB7839E Q34130097-5E8262B3-D6FC-452A-8FFE-D4B5DA61BABB Q34252907-E0105191-9943-41D0-AE7E-5498CB179888 Q34605304-15A3C91F-CE95-4652-BB2C-5C92F2C6C3E7 Q34627624-8E5ABF29-AB33-486F-9EFE-A45F23207F74 Q34631714-D35AC6BB-E3E2-4CCC-90E2-422F06ED9B66 Q34635335-69057D2B-BC01-425D-8FD2-6DE32FBDBFBD Q35811581-4BAD4F9F-21B9-4E80-A1F0-834FA3646F61 Q36531658-03BBC791-B946-4924-96F7-077E3FA811E3 Q36775716-8F56F740-538D-4235-AE0D-DA3635391AAA Q37004031-28A1F6BB-A6B6-4906-8D6B-4A0E923D261C Q37218993-CA64E62F-868F-4ED4-95CC-425AACC8ACC7 Q37338120-9E49ED97-2AC7-4BBB-8985-C13DF6FE5052 Q37377940-C8590BA0-8328-470B-8EFC-FE18ACE5FCE0 Q37383508-E75298B1-169A-4991-9DAB-968210DD1218 Q37470692-14C873DA-4366-4489-9D20-60B8E67A052C Q37510966-8711FDDE-E5BC-4B79-8901-A3DC93884328 Q37756353-4A7D5C7B-B65E-4781-9F85-865A93178E29 Q37765619-3D471F3E-5763-4F3C-B5B0-E258EB82B948 Q37810274-B41BF720-355B-42DF-BECA-DBB1F32652ED Q37848142-01988BB9-3089-4D1E-8D87-F4928835EC2A Q37857332-F4C8BA68-38E4-4832-93AB-1062FCA63D73 Q37872338-4C764D37-8A95-4ED3-A42C-48D8417C0433 Q37873499-ADD6345D-4857-434C-8846-449929BE71A5 Q37907319-9E9273CD-B180-492C-BBF7-4E2895E4C468 Q37924879-306966FE-D0B9-4FBE-850E-D012300C7FA3 Q37978093-4DBFF316-3CE6-4FC9-A581-02391641B69E Q38009353-527E02E4-BFFA-4DDA-8743-43D50F845F5A Q38038959-F85D3595-3067-48EB-9BA9-BE18A15167E8 Q38071973-62FDC7D7-2B4B-4BDE-9BFF-BCFB47762CF1 Q38087189-B670F862-A791-4468-9974-A6F872DF558E Q38124868-11EBAF2D-C8C2-40AF-8A1C-DBE2CE3242D3 Q38155933-D85779ED-9392-4953-BB4B-0E149795DF5C Q38170106-3C1D07C3-DCE7-4BD4-8999-5EE55366536B

P2860

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

http://www.wikidata.org/entity/Q28200198

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@ast

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@en

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@nl

type

label

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@ast

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@en

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@nl

prefLabel

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@ast

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@en

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@nl

P1433

Q28200198-65BE207E-D387-4A78-8B8D-A6CDEDF7E1EF

P1476

Q28200198-5139A92E-6E04-4EFE-AF41-85D6F6819AD3

P2093

Q28200198-2CDFC98F-D30F-463C-97C9-DCDBB66C56D3

Q28200198-3A6211F4-36E7-4A96-B130-E863EF70498F

Q28200198-5D09176C-FA03-4C06-BB35-B06F89A176D3

Q28200198-DF778BBE-069D-4C6A-871C-FD44BF0ADC78

P2860

Q28200198-0F64845B-A0D2-4282-ADC6-67A92200F732

Q28200198-174F9F6E-5EC6-433A-A248-95FF8E71BE45

Q28200198-29112B79-3E9C-46FE-AA52-DEA45EAD3EC3

Q28200198-2D4331D6-51E2-438E-BAE5-995FED1C2ED6

Q28200198-78CBD7C1-B9CD-4452-9A3E-FB11643A723B

Q28200198-8BA8F603-B874-4A5E-A009-7C84E5A86C76

Q28200198-8E1B765E-3B33-4EF4-8350-3614E314014A

Q28200198-95A96C62-8A24-4B39-ADB0-D0CC08628768

Q28200198-9B1E31C9-62D6-4882-90EB-B93330855CCA

Q28200198-A0300EB0-35A5-4258-91C2-29D8D133797D

P304

Q28200198-99501D5A-FE2D-462A-BFEE-2C2AFE9724CB

P31

Q28200198-CB20D914-C3A9-4FC0-91C0-F081F5AFB0ED

P356

Q28200198-43EE6279-BCD1-4897-A5C6-C837AED732CB

P407

Q28200198-241CA19B-0049-495C-8F1E-62229A8A8E04

P433

Q28200198-B2AF0A88-1528-47D1-96C1-F487FCCE1CBC

P478

Q28200198-2902D13F-98B4-4DF1-A71D-07C5EBD5D897

P577

Q28200198-A516EBB3-4735-4F03-A7CA-F86E7B8D5E7E

P698

Q28200198-212BB5DE-C052-4B68-B266-A1352BF354CD

P921

Q28200198-637EE8F5-6F41-445A-9823-8D24080BA8C4

Q28200198-86AD616B-86B5-4DC8-870E-AB1201FDE127

Q28200198-AD917DD1-A7AC-4D20-8A5E-891FE6DD9B61

P356

0091270006292127

P1433

The Journal of Clinical Pharmacology

P1476

Safety, tolerability, pharmaco ...... r--are not affected by aspirin

@en

P2093

Dagmar Kubitza

http://www.w3.org/2001/XMLSchema#string

Michael Becka

http://www.w3.org/2001/XMLSchema#string

Michael Zuehlsdorf

http://www.w3.org/2001/XMLSchema#string

Wolfgang Mueck

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

Aspirin and postoperative bleeding after coronary artery bypass grafting

Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

P304

981-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270006292127

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16920892

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

pharmacodynamics